Literature DB >> 35043005

The use of supercytokines, immunocytokines, engager cytokines, and other synthetic cytokines in immunotherapy.

Xiaohu Zheng1,2,3,4, Yaqi Wu5, Jiacheng Bi6,7, Yingying Huang6,7, Ying Cheng8, Yangyang Li8, Yuwei Wu8, Guoshuai Cao8, Zhigang Tian9,10,11,12.   

Abstract

Cytokines exert powerful immunomodulatory effects that are critical to physiology and pathology in humans. The application of natural cytokines in clinical studies has not been clearly established, and there are often problems associated with toxicity or lack of efficacy. The key reasons can be attributed to the pleiotropy of cytokine receptors and undesired activation of off-target cells. With a deeper understanding of the structural principles and functional signals of cytokine-receptor interactions, artificial modification of cytokine signaling through protein engineering and synthetic immunology has become an increasingly feasible and powerful approach. Engineered cytokines are designed to selectively target cells. Herein, the theoretical and experimental evidence of cytokine engineering is reviewed, and the "supercytokines" resulting from structural enhancement and the "immunocytokines" generated by antibody fusion are described. Finally, the "engager cytokines" formed by the crosslinking of cytokines and bispecific immune engagers and other synthetic cytokines formed by nonnatural analogs are also discussed.
© 2021. The Author(s), under exclusive licence to CSI and USTC.

Entities:  

Keywords:  Supercytokines; engager cytokines; immunocytokines; immunotherapy; synthetic cytokines

Mesh:

Substances:

Year:  2022        PMID: 35043005      PMCID: PMC8803834          DOI: 10.1038/s41423-021-00786-6

Source DB:  PubMed          Journal:  Cell Mol Immunol        ISSN: 1672-7681            Impact factor:   11.530


  151 in total

1.  Targeted delivery of tumor necrosis factor-alpha to tumor vessels induces a therapeutic T cell-mediated immune response that protects the host against syngeneic tumors of different histologic origin.

Authors:  Enrica Balza; Lorenzo Mortara; Francesca Sassi; Stefano Monteghirfo; Barbara Carnemolla; Patrizia Castellani; Dario Neri; Roberto S Accolla; Luciano Zardi; Laura Borsi
Journal:  Clin Cancer Res       Date:  2006-04-15       Impact factor: 12.531

2.  Converting IL-15 to a superagonist by binding to soluble IL-15R{alpha}.

Authors:  Mark P Rubinstein; Marek Kovar; Jared F Purton; Jae-Ho Cho; Onur Boyman; Charles D Surh; Jonathan Sprent
Journal:  Proc Natl Acad Sci U S A       Date:  2006-06-06       Impact factor: 11.205

3.  Novel CD19-targeted TriKE restores NK cell function and proliferative capacity in CLL.

Authors:  Martin Felices; Behiye Kodal; Peter Hinderlie; Michael F Kaminski; Sarah Cooley; Daniel J Weisdorf; Daniel A Vallera; Jeffrey S Miller; Veronika Bachanova
Journal:  Blood Adv       Date:  2019-03-26

Review 4.  IL-2: the first effective immunotherapy for human cancer.

Authors:  Steven A Rosenberg
Journal:  J Immunol       Date:  2014-06-15       Impact factor: 5.422

Review 5.  Revisiting IL-2: Biology and therapeutic prospects.

Authors:  Abul K Abbas; Eleonora Trotta; Dimitre R Simeonov; Alexander Marson; Jeffrey A Bluestone
Journal:  Sci Immunol       Date:  2018-07-06

6.  Synergistic therapeutic effects of a tumor targeting antibody fragment, fused to interleukin 12 and to tumor necrosis factor alpha.

Authors:  Cornelia Halin; Verena Gafner; Maria Elena Villani; Laura Borsi; Alexander Berndt; Hartwig Kosmehl; Luciano Zardi; Dario Neri
Journal:  Cancer Res       Date:  2003-06-15       Impact factor: 12.701

Review 7.  The IL-2 cytokine family in cancer immunotherapy.

Authors:  Geok Choo Sim; Laszlo Radvanyi
Journal:  Cytokine Growth Factor Rev       Date:  2014-08-01       Impact factor: 7.638

8.  Combination Therapy with NHS-muIL12 and Avelumab (anti-PD-L1) Enhances Antitumor Efficacy in Preclinical Cancer Models.

Authors:  Chunxiao Xu; Yanping Zhang; P Alexander Rolfe; Vivian M Hernández; Wilson Guzman; Giorgio Kradjian; Bo Marelli; Guozhong Qin; Jin Qi; Hong Wang; Huakui Yu; Robert Tighe; Kin-Ming Lo; Jessie M English; Laszlo Radvanyi; Yan Lan
Journal:  Clin Cancer Res       Date:  2017-07-05       Impact factor: 12.531

9.  NKTR-214, an Engineered Cytokine with Biased IL2 Receptor Binding, Increased Tumor Exposure, and Marked Efficacy in Mouse Tumor Models.

Authors:  Deborah H Charych; Ute Hoch; John L Langowski; Steve R Lee; Murali K Addepalli; Peter B Kirk; Dawei Sheng; Xiaofeng Liu; Paul W Sims; Laurie A VanderVeen; Cherie F Ali; Thomas K Chang; Marina Konakova; Rhoneil L Pena; Rupesh S Kanhere; Yolanda M Kirksey; Chunmei Ji; Yujun Wang; Jicai Huang; Theresa D Sweeney; Seema S Kantak; Stephen K Doberstein
Journal:  Clin Cancer Res       Date:  2016-02-01       Impact factor: 12.531

10.  Redirecting cell-type specific cytokine responses with engineered interleukin-4 superkines.

Authors:  Ilkka S Junttila; Remi J Creusot; Ignacio Moraga; Darren L Bates; Michael T Wong; Michael N Alonso; Megan M Suhoski; Patrick Lupardus; Martin Meier-Schellersheim; Edgar G Engleman; Paul J Utz; C Garrison Fathman; William E Paul; K Christopher Garcia
Journal:  Nat Chem Biol       Date:  2012-10-28       Impact factor: 15.040

View more
  4 in total

Review 1.  Nanobiotherapeutic strategies to target immune microenvironment of triple-negative breast cancer.

Authors:  Qing Chang; Liang Chang; Mo Li; Liwen Fan; Shunchao Bao; Xinyu Wang; Linlin Liu
Journal:  Am J Cancer Res       Date:  2022-09-15       Impact factor: 5.942

Review 2.  Natural killer cell homing and trafficking in tissues and tumors: from biology to application.

Authors:  Guang He Ran; Yu Qing Lin; Lei Tian; Tao Zhang; Dong Mei Yan; Jian Hua Yu; You Cai Deng
Journal:  Signal Transduct Target Ther       Date:  2022-06-29

Review 3.  Immunogenic Cell Death Activates the Tumor Immune Microenvironment to Boost the Immunotherapy Efficiency.

Authors:  Zhilin Li; Xiaoqin Lai; Shiqin Fu; Long Ren; Hao Cai; Hu Zhang; Zhongwei Gu; Xuelei Ma; Kui Luo
Journal:  Adv Sci (Weinh)       Date:  2022-06-02       Impact factor: 17.521

Review 4.  Radioimmunotherapy in HPV-Associated Head and Neck Squamous Cell Carcinoma.

Authors:  Xin Zhou; Xiaoshen Wang
Journal:  Biomedicines       Date:  2022-08-17
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.